Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Non Operating Income (2017 - 2025)

Organogenesis Holdings has reported Non Operating Income over the past 9 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Non Operating Income at $2.2 million for Q4 2025, up 8185.19% from a year ago — trailing twelve months through Dec 2025 was $3.4 million (up 16700.0% YoY), and the annual figure for FY2025 was $2.3 million, up 11280.0%.
  • Non Operating Income for Q4 2025 was $2.2 million at Organogenesis Holdings, up from $433000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for ORGO hit a ceiling of $2.2 million in Q4 2025 and a floor of -$3.4 million in Q3 2021.
  • Median Non Operating Income over the past 5 years was -$18000.0 (2021), compared with a mean of -$119200.0.
  • Peak annual rise in Non Operating Income hit 22822.22% in 2022, while the deepest fall reached 24566.67% in 2022.
  • Organogenesis Holdings' Non Operating Income stood at -$9000.0 in 2021, then soared by 22822.22% to $2.0 million in 2022, then decreased by 18.68% to $1.7 million in 2023, then crashed by 101.62% to -$27000.0 in 2024, then surged by 8185.19% to $2.2 million in 2025.
  • The last three reported values for Non Operating Income were $2.2 million (Q4 2025), $433000.0 (Q3 2025), and $742000.0 (Q2 2025) per Business Quant data.